Immunotoxins and ABT-737 as single agents have, nevertheless, been shown to be effective in hematological tumors, where in fact one immunoconjugate consisting of an IL-2 fused to a modified Diphteria toxin (Ontak®) is approved by the Food and Drug Administration is an option for patient with cutaneous T-cell lymphoma. This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.